SCHEMBL334268

SCHEMBL334268

CC(C)Oc1ccc(-n2c(CC(=O)O)c(C(=O)O)c3cc(Oc4cccc(C(=O)O)c4)ccc32)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.41
THRB P10828 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
AKR1C3 P42330 1/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.39
POLB P06746 1/20 0.39
CYP2C9 P11712 1/20 0.39
RAB9A P51151 1/20 0.39
USP14 P54578 1/20 0.39
PKM P14618 1/20 0.39
BCL2 P10415 1/20 0.39
MDM2 Q00987 1/20 0.39
MCL1 Q07820 1/20 0.39
KMO O15229 1/20 0.38
MAPT P10636 3/20 0.38
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
RXRA P19793 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL333497 0.90 USP14 (0.44) KDM4EKMT2AMEN1USP14BCL2
SCHEMBL503756 0.89 USP14 (0.45) KDM4EKMT2AMEN1USP14BCL2
SCHEMBL333231 0.87 MEN1 (0.48) KDM4ESMN1; SMN2AKR1C3KMT2AMEN1
SCHEMBL360369 0.87 PPARG (0.47) KDM4ETHRBKMT2AMEN1USP14
SCHEMBL333817 0.87 PPARG (0.52) AKR1C3PPARGPPARAPTGES
SCHEMBL503872 0.87 USP14 (0.48) KDM4EAKR1C3KMT2AMEN1CYP2C9
SCHEMBL334235 0.87 BCL2 (0.42) KDM4ETHRBSMN1; SMN2KMT2AMEN1
SCHEMBL503499 0.85 MDM2 (0.45) KDM4EKMT2AMEN1USP14BCL2
SCHEMBL334350 0.85 PTGES (0.52) KDM4EKMT2AMEN1PPARGPPARA
SCHEMBL335371 0.85 USP14 (0.41) KDM4ETHRBSMN1; SMN2USP14BCL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097623-B2 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics BIOLIPOX AB (SE) 2012-01-17 US disclosed
EP-1841735-B1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2011-03-09 EP disclosed
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2009-03-19 US disclosed
EP-1841735-A1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION Biolipox AB (SE) 2007-10-10 EP disclosed
WO-2006077366-A1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation IDO1, IDO2, AREG KDM4E 1104/4885THRB 575/4885SMN1; SMN2 3963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.